Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neumora Therapeutics, Inc. - Common Stock
(NQ:
NMRA
)
11.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neumora Therapeutics, Inc. - Common Stock
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
August 14, 2024
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
June 20, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
May 14, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 06, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 15, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 22, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
December 12, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
November 27, 2023
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 01, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in November
October 30, 2023
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
October 10, 2023
Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines
From
Neumora Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.